Institutional shares held 111 Million
2.63M calls
845K puts
Total value of holdings $2.15B
$50.9M calls
$16.3M puts
Market Cap $2.12B
109,865,000 Shares Out.
Institutional ownership 101.45%
# of Institutions 299


Latest Institutional Activity in APLS

Top Purchases

Q1 2025
Sg Americas Securities, LLC Shares Held: 366K ($7.08M)
Q1 2025
Assenagon Asset Management S.A. Shares Held: 74.3K ($1.44M)
Q1 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 70.2K ($1.36M)
Q1 2025
Pallas Capital Advisors LLC Shares Held: 42.5K ($822K)
Q1 2025
Merit Financial Group, LLC Shares Held: 33.8K ($653K)

Top Sells

Q1 2025
Gamma Investing LLC Shares Held: 468 ($9.05K)
Q1 2025
Rhumbline Advisers Shares Held: 124K ($2.41M)
Q1 2025
Quintet Private Bank (Europe) S.A. Shares Held: 452 ($8.74K)
Q1 2025
Versant Capital Management, Inc Shares Held: 166 ($3.21K)
Q1 2025
Advisor Net Financial, Inc Shares Held: 415 ($8.02K)

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.


Insider Transactions at APLS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
577K Shares
From 21 Insiders
Grant, award, or other acquisition 420K shares
Exercise of conversion of derivative security 125K shares
Bona fide gift 31.4K shares
Sell / Disposition
471K Shares
From 15 Insiders
Open market or private sale 257K shares
Bona fide gift 31.4K shares
Other acquisition or disposition 182K shares

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS